Characterization of the HER2 status in BRCA-mutated breast cancer: a single institutional series and systematic review with pooled analysis

G. Tomasello1*, D. Gambini1, F. Petrelli2, J. Azzollini3, C. Arcanà1, M. Ghidini1, B. Peissel3, S. Manoukian1, & O. Garrone1

1Medical Oncology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan; 2Oncology Unit, ASST Bergamo Ovest, Treviglio, Italy (BG); 3Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

Available online 8 July 2022

Background: Pathogenic variants (PVs) in BRCA1/2 genes account for ~6% of breast and 20% of ovarian cancers. Most breast tumors developed by BRCA1 carriers are triple negative. BRCA2 tumors have similar rates of estrogen receptor positivity as sporadic controls but are less likely to be human epidermal growth factor receptor 2 (HER2)-positive. Prevalence of HER2 positivity among breast cancers (BCs) in BRCA1/2 mutation carriers is poorly and variably described, ranging from 0% to 10% and 0% to 13% in BRCA1 and BRCA2 carriers, respectively.

Patients and methods: We assessed the prevalence of HER2 positivity among a single institutional cohort of 398 BCs developed in carriers of BRCA1/2 PVs (240 BRCA1, 158 BRCA2). Subsequently, a systematic review of the literature and pooled analysis was carried out.

Results: In our series we found a 7% HER2 positivity rate among all first BRCA1/2 BCs overall. In BRCA1 carriers, 5.4% of BCs were HER2-positive compared with 9.5% in BRCA2-mutated patients. Among bilateral BCs, HER2-positive cases were 15.2% in the BRCA1 group and 23.1% in the BRCA2 group. Notably, six BRCA1 and eight BRCA2 carriers showed discordant HER2 status between BC and bilateral BC (23.7%, 14/59). The systematic review included 21 083 BRCA1/2 patients from 73 eligible studies. The pooled rate of BRCAmut/HER2-positive BCs is 9.1% (95% confidence interval 7.3% to 11.2%), BRCA1 and BRCA2 when reported as separate data ranged from 0% to 33.3% (mean 8.3%) and from 0% to 86% (mean 10.3%), respectively.

Conclusions: As compared with sporadic cases, BCs occurring in BRCA1 and/or BRCA2 PVs carriers are less frequently HER2-positive. Prevalence of HER2 positivity in our series was consistent with pooled analysis and did not exceed 10%. Although not common, co-existence of BRCA mutations and HER2 overexpression and/or gene amplification should be acknowledged. More research is needed to better characterize this subgroup of patients who should not be excluded a priori from clinical trials of targeted therapy for BRCA1/2-driven cancers.

Key words: breast cancer, HER2-positive, BRCA1, BRCA2

INTRODUCTION

Breast cancer (BC) is a heterogeneous disease, with different molecular subtypes identified by gene expression profiling analyses [Luminal A, Luminal B, human epidermal growth factor receptor 2 (HER2)-enriched, basal-like/triple-negative].1,2 HER2 belongs to the epidermal growth factor receptor family, and gene amplification or protein overexpression are observed in up to 20% of all BCs, usually associated with poor prognosis.3-5 The first developed therapy targeting HER2 was trastuzumab, a monoclonal antibody first licensed by the Food and Drug Administration in 1998 in the advanced setting, followed by other drugs, for early and/or advanced disease (monoclonal antibodies, tyrosine kinase receptor inhibitors, antibody-drug conjugates), with a significant prognostic improvement.

To date, many HER2-targeted therapies are available, but patients with HER2-positive BC are usually not eligible in clinical trials exploring drug activities against other targets, even if expressed. This is the case of BC associated to germline variants of BRCA1 and BRCA2, which are the two major genes underlying hereditary breast and ovarian cancer (HBOC).6 As for BC, up to 15% of all new cases are attributable to a familial or hereditary condition. Among
these, *BRCA1* and *BRCA2* are the genes most frequently involved, playing an important role in maintaining the genomic stability, especially participating in the homologous recombination repair (HRR) of DNA double-strand breaks.7

Tumors with HRR deficiency, such as ovarian and breast *BRCA*-mutant cancers, show a greater sensibility to drugs causing DNA damages, such as platinum compounds and poly(ADP-ribose)polymerase (PARP) inhibitors. Especially causing DNA damages, such as platinum compounds and *BRCA* gene, 10-12 As for *BRCA2* tumors, similar rates of ER positivity as sporadic controls are described, but HER2-positive cases are also infrequent. The prevalence of HER2 positivity among *BRCA1*/2 mutation carriers is poorly and variably described in literature, ranging from 0% to 10% and 0% to 13% in *BRCA1* and *BRCA2* carriers, respectively.13

In order to analyze the prevalence and the characteristics of HER2-positive BC in this setting, we retrospectively reviewed our single institutional series of BCs in *BRCA1*/2 mutation carriers. Moreover, we carried out a systematic review of the literature, with the aim of characterizing the subgroup of *BRCA1*/2-mutated patients with concomitant HER2-positive BC.

**MATERIAL AND METHODS**

**Single institutional study cohort**

To assess the relationship between HER2 status in BC and the presence of pathogenic/likely pathogenic variants (PVs) of the *BRCA1* and *BRCA2* genes in our population, we selected a study cohort among individuals who underwent genetic counseling and *BRCA1*/2 testing at the Medical Genetics Unit of Fondazione IRCCS Istituto Nazionale dei Tumori of Milan from January 1996 to April 2021.

Among the 6144 individuals tested due to significant personal or family history, belonging to 3940 families, we selected only female carriers of *BRCA1* or *BRCA2* PVs, classified according to the Evidence-based Network for the Interpretation of Mutant Alleles (ENIGMA) consortium guidelines ([https://enigmaconsortium.org/](https://enigmaconsortium.org/)), affected by invasive BC and for whom data on HER2 expression were available. Patients who developed bilateral BC (BBC) or more than one ipsilateral or BBC were included only if the HER2 status was available for at least one tumor on each side. Ductal carcinomas *in situ* were not included in the analysis. Clinical and pathological data, including age at tumor diagnosis, timing of chemotherapy in relation to the collection of the surgical specimens, tumor histology, grade, and hormone receptor status were retrieved for all patients.

**Systematic review and pooled analysis**

**Search strategy and inclusion criteria.** Subsequently, a systematic review was carried out according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. A bibliographical search was carried out in Medline (PubMed), Embase, and Cochrane library—Cochrane Central Register of Controlled Trials (CENTRAL). The last search date was 30 September 2021.

The following terms were used in combination with Boolean operators (AND, OR, NOT): (*breast neoplasms*[MeSH Terms] OR (*breast*[All Fields] AND * neo-plasms*[All Fields]) OR *breast neoplasms*[All Fields] OR (*breast*[All Fields] AND *cancer*[All Fields]) OR *breast cancer*[All Fields]) AND (*brca1 s*[All Fields] OR *genes, brca1*[MeSH Terms] OR (*genes*[All Fields] AND *brca1*[All Fields])) OR *brca1 genes*[All Fields] OR *brca1*[All Fields]) OR (*genes, brca2*[MeSH Terms] OR (*genes*[All Fields] AND *brca2*[All Fields]) OR *brca2 genes*[All Fields] OR *brca2*[All Fields]) AND (*HER2-positive*[All Fields] OR *Erb-B2*[All Fields] OR *HER2-neu*[All Fields]). Two independent authors (FP and GT) searched for potentially eligible articles retrieved by the initial search, and potential disagreements were resolved by consensus with a third reviewer (CA). References of the included studies and any previously published systematic reviews were manually assessed in order to detect any missing study.

Studies were considered eligible if: (i) they reported on the frequency of patients with *BRCA*-mutated (mut)/HER2-positive BC, (ii) they provided data on the outcomes or other associated clinical characteristics independent of tumor stage and treatment, (iii) at least 10 BC patients were evaluated, and (iv) they were published in the English language.

Exclusion criteria included (i) preclinical or pediatric studies, (ii) studies reporting on patients with cancers outside of the breast, (iii) reviews and meta-analyses, (iv) case reports, editorials, and letters to the editors, and (v) overlapping studies. In the case of duplicate publications, only the most recent or most informative study was included in the analyses. Articles that fulfilled the inclusion criteria were retrieved for full-text evaluation.

**Data extraction.** After reviewing the full texts of eligible studies, two independent authors (GT, CA) carried out the data extraction and crosschecked all results. Potential discrepancies in the selection of articles and the extraction of the data were resolved following consensus with a third reviewer (FP).

Extracted variables included general study characteristics (author, year of publication, study design, number of all *BRCA*-mutated patients and *BRCA*mut/HER2-positive patients, follow-up), *ER*+ status, other hereditary alterations, treatment received, and outcome.

**Statistical analysis.** Descriptive statistics were reported as total and percentage for categorical variables and as median (range) or mean ± standard deviation for continuous variables, unless otherwise indicated. The meta-analysis of survival data was carried out with the RevMan software (version 5.4; The Nordic Cochrane Centre (Copenhagen, Denmark).
Main features of first invasive breast cancers (BC) and bilateral breast cancers (BBC) in our cohort of BRCA1/2 pathogenic variants carriers

| BC, N (%) | BBC, N (%) |
|-----------|------------|
| Gene      |            |
| BRCA1     | 240 (60.3) |
| BRCA2     | 158 (39.7) |
| Neoadjuvant chemotherapy | |
| No        | 390 (98)   |
| NA        | 4 (1)      |
| Histotype |            |
| Ductal    | 322 (80.9) |
| Lobular   | 21 (5.3)   |
| Mixed     | 14 (3.5)   |
| Medullary | 19 (4.8)   |
| Other     | 7 (1.7)    |
| NA        | 15 (3.8)   |
| Grade     |            |
| I         | 0          |
| II        | 122 (30.7) |
| III       | 248 (62.3) |
| NA        | 28 (7)     |
| Estrogen receptor status | |
| Positive  | 183 (46)   |
| Negative  | 213 (53.5) |
| NA        | 2 (0.5)    |
| Progesterone receptor status | |
| Positive  | 148 (37.2) |
| Negative  | 246 (61.8) |
| NA        | 4 (1)      |
| HER2 status |        |
| Positive  | 28 (7)     |
| Negative  | 370 (93)   |
| Triple-negative breast cancer | 189/399 (48) |

For 34 patients, who developed more than one ipsilateral BC, and six patients, who developed more than one BBC, the first BC/BBC was not included due to the unavailable HER2 status.

Results

Single institutional study cohort

The analyzed cohort was composed of 398 female carriers of BRCA1/2 PVs (240 BRCA1, 158 BRCA2), including 288 probands and 110 family members, who developed at least one invasive BC. A subgroup of 59 patients (33 BRCA1, 26 BRCA2) developed BBC. Pathological characteristics of both BCs and BBCs are reported in Table 1. Additionally, the main features of HER2-positive first invasive BCs and BBCs in our cohort of BRCA1/2 PVs carriers are described in Table 2.

The median age at diagnosis was 42 years (range 22-84 years) for the first BC and 47 years (range 32-76 years) for BBC. More than 80% of the considered tumors were invasive ductal carcinomas and ~60% were high grade. For both the first BCs and BBCs, pathology assessment was mostly carried out on surgical specimens collected before chemotherapy.

Results

Single institutional study cohort

The analyzed cohort was composed of 398 female carriers of BRCA1/2 PVs (240 BRCA1, 158 BRCA2), including 288 probands and 110 family members, who developed at least one invasive BC. A subgroup of 59 patients (33 BRCA1, 26 BRCA2) developed BBC. Pathological characteristics of both BCs and BBCs are reported in Table 1. Additionally, the main features of HER2-positive first invasive BCs and BBCs in our cohort of BRCA1/2 PVs carriers are described in Table 2.

The median age at diagnosis was 42 years (range 22-84 years) for the first BC and 47 years (range 32-76 years) for BBC. More than 80% of the considered tumors were invasive ductal carcinomas and ~60% were high grade. For both the first BCs and BBCs, pathology assessment was mostly carried out on surgical specimens collected before chemotherapy.

Among all first BCs, 7% (28/398) were HER2-positive and 93% (370/398) were HER2-negative. No significant difference in the HER2 status was detected between probands (HER2-positive 7.3%, 21/288) and family members (HER2-negative 6.4%, 7/110).

In carriers of BRCA1 PVs, 5.4% (13/240) of BCs were HER2-positive compared with 9.5% (15/158) in carriers of BRCA2 PVs. As concerns BBC, HER2-positive cases were 15.2% (5/33) in the BRCA1 group and 23.1% (6/26) in the BRCA2 (Figure 1).

Notably, six BRCA1 and eight BRCA2 PV carriers showed discordant HER2 status between BC and BBC (23.7%, 14/59). Of these patients, 78.6% (11/14) developed an HER2-negative BC followed by HER2-positive BBC, whereas 21.4% (3/14) developed an HER2-positive BC followed by HER2-negative BBC (Figure 2).

Systematic review and pooled analysis

Identification of eligible studies. The flow of article selection process is depicted in Figure 3. After screening 544 records, 73 studies finally met the predefined criteria and were considered eligible for inclusion in the systematic review. Descriptive characteristics of the eligible studies are summarized in Supplementary Table S1, available at https://doi.org/10.1016/j.esmoop.2022.100531. A total of 58 studies were retrospective; 11 were prospective cohorts; 1 was a cross-sectional study, 2 were case control studies, and 1 was both prospective and retrospective. Patients were analyzed from 1960 to 2014. Three studies were excluded because two did not report data about BRCAmut/HER2-positive patients and one was a case report.

Patient characteristics. Among the included studies, a total of 21 083 patients had BRCA1 or 2 mutations (Supplementary Table S1, available at https://doi.org/10.1016/j.esmoop.2022.100531).
Findings from our study confirm the low frequency of HER2-positive BCs among BRCA1/BRCA2 PVs carriers. This is particularly evident for BRCA1, and data from our cohort are strongly consistent with the results of the pooled analysis. Specifically, we found a 7% HER2 positivity rate among all first BRCA1/2 BCs analyzed in our cohort study, which is in line with the 9% rate obtained from the pooled analysis of BRCAmut/HER2-positive BCs. Indeed, our series is one of the largest ever published and similar to the few studies previously reported confirms that compared with BRCA1, the expected prevalence of HER2 positivity among BRCA2 is higher.

Cancer development is a multistep process where genomic instability plays a pivotal role. Germline mutations of BRCA1 and BRCA2 are well-known gene-driven mechanisms of carcinogenesis and represent a major risk factor for multiple tumors, with a peculiar selectivity for breast and ovarian cancers. Biological processes leading to cancer transformation involving breast cells harboring such mutations are complex and still not completely elucidated, including maintenance of the genomic integrity, regulation of the oxidative stress and protein stability, modulation of gene transcription, cell cycle progression, and therapy resistance.88

Similarly, the HER2 gene is critical for the activation of subcellular signal transduction pathways controlling epithelial cell growth and differentiation87 and its amplification or protein overexpression are established predictive biomarkers of benefit from anti-HER2 therapy. When BRCA1/BRCA2 PVs and HER2 are simultaneously present, however, no studies have evaluated the different contribution of either alteration as oncogenic drivers. Additionally, it is currently unknown if such molecular biomarkers may functionally act in a mutually exclusive manner in the BC transformation process.

An original finding of our work is represented by the nearly 25% discordance rate registered among all BCs. Noteworthy, the great majority of these patients [i.e. 78.6% (11/14)] first developed an HER2-negative BC followed by an HER2-positive BBC. This might be the result of the predominant role of BRCA-driven mechanisms in the early BC transformation process. Some considerations are supporting the hypothesis that such molecular alterations might be mutually exclusive.

First, the significant lower prevalence of HER2 positivity in BRCA1/BRCA2 PVs carriers compared with sporadic cancers. Second, the partial discordance in HER2 status in the second contralateral breast tumor, compared with the first mainly HER2-negative tumor.

Additionally, such tumors usually develop at a young age, highlighting the key contribution of germline mutations.

Third, as demonstrated by a recent analysis of a cohort of BC patients with Li Fraumeni syndrome, the presence of a germline variant of TP53 did not correlate with a lower frequency of HER2 status as compared with the sporadic counterpart. In fact, despite the limitation due to the relatively small sample in a syndrome rarer than HBOC, the rate of observed HER2-enriched TP53-mutated BCs was ~33% (11/32).88 This last finding could also raise the hypothesis of not only a predominance, but potentially a
‘silencing’ of the HER2 pathway by the BRCA-mutated status.

Due to reduced DNA repair capacity, BRCA-mutated cancers are also more responsive to the distinct types of treatment such as platinum-based compounds and PARP inhibitors, which induce accumulation of DNA double-strand breaks. In BRCA1 and BRCA2 PVs BC carriers, the overexpression and/or amplification of the HER2 gene have always represented an exclusion criterion for enrollment in clinical trials with PARP inhibitors. As a matter of fact, members of this class of targeted agents, such as olaparib and talazoparib, have been globally approved for patients with germline BRCA mutations and HER2-negative advanced BC who have previously been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic disease setting. Olaparib has also received indication for BRCA carriers with early-stage, high-risk HER2-negative BC.

Very recently, some trials have been designed to also allow inclusion of the specific cohort of HER2-positive patients.

In particular, a phase II trial (‘OPHELIA’, NCT03931551) is recruiting HER2-positive BC subjects with gene alterations in HRR DNA pathway (including germline deleterious mutations in BRCA1 or BRCA2 genes) and aims at evaluating the efficacy of the association of olaparib and trastuzumab. Finally, although not selectively designed for the cohort of BRCA1/2-mutated BCs, an interesting phase I trial (NCT04585958) is enrolling patients with HER2-positive solid tumors in order to evaluate the safety and tolerability of the combination of trastuzumab deruxtecan (DS-8201a) with olaparib.

The present study does have some limitations. All studies included in the systematic review and pooled analysis are retrospective, and the only possible way to perform correlation with any pathologic feature was with ER status. No information relative to overall survival of BRCA mut/HER2-positive cases compared with HER2-negative counterparts was available. Additionally, the older series included patients treated with obsolete therapies so that a comparison with the modern era is not feasible, and treatment received is almost entirely not reported. The analysis of the HER2 status was also carried out with old techniques so that strict definition as currently proposed was likely not applicable in these series. Finally, median follow-up was not reported in most series, therefore potential observation length bias is possible.

In conclusion, this study confirms that BCs occurring in germline BRCA1/2 PVs carriers are rarely HER2-positive. Although not common, the co-existence of BRCA mutations and HER2 overexpression and/or gene amplification should
be acknowledged and drugs like PARP inhibitors possibly considered. More research is needed to better characterize this subgroup of patients who should not be excluded a priori from clinical trials of targeted therapy for BRCA1/2-driven cancers.

**FUNDING**

Italian Ministry of Health - Current research IRCCS [grant number RC21 18501].

**DISCLOSURE**

GT reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Eli Lilly, Novartis, Amgen, Roche, Merck. Support for attending meetings and/or travel: Eli Lilly. Participation on a Data Safety Monitoring Board or Advisory Board: Amgen, Roche, Eli Lilly.

OG reports consulting fees: Eisai, Eli-Lilly, MSD, Seagen. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Novartis, Eli Lilly, Eisai.

MG reports consulting fees: Amgen, Merck, Lilly. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Italfarmaco, Merck, Servier. Participation on a Data Safety Monitoring Board or Advisory Board: Roche, Servier.

All other authors have declared no conflicts of interest.

**REFERENCES**

1. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci U S A.* 2001;98:10869-10874.

2. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proc Natl Acad Sci U S A.* 2003;100:8418-8423.

3. Parise CA, Caggiano V. Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. *J Cancer Epidemiol.* 2014;2014:469251.

4. Paterson MC, Dietrich KD, Danyluk J, et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. *Cancer Res.* 1991;51:556-567.

5. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. *Oncologist.* 1998;3:237-252.

6. Petrucelli N, Daly MB, Pal T. BRCA1-and BRCA2-associated hereditary breast and ovarian cancer. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews(R). Seattle (WA); University of Washington, Seattle; 1993–2022. 1998 [updated 2022 May 26].

7. Yoshida R. Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. *Breast Cancer. 2021;28:1167-1180.*

8. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. *N Engl J Med.* 2017;377:523-533.

9. Tutt AN, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1-or BRCA2-mutated breast cancer. *N Engl J Med.* 2021;384:2394-2405.

10. Küchenbaecker KB, Neuhausen SL, Robson M, et al. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res.* 2014;16:3416.
carcinomas in a hospital-based sample of Dutch breast cancer patients.

31. De Taillhout S, Peron J, Vuijlemeier A, et al. Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes. Sci Rep. 2020;10:7073.

32. Deb S, Jene N, Korfal F, Fox SB. Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas. BMC Cancer. 2012;12:510.

33. Eccles DM, Li N, Handwerker R, et al. Genetic testing in a cohort of young patients with HER2-amplified breast cancer. Ann Oncol. 2016;27:467-473.

34. Eerola H, Heinonen M, Heikkilä P, et al. Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res. 2008;10:R17.

35. Ellingson MS, Hart SN, Kalari KR, et al. Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy. Breast Cancer Res Treat. 2015;153:435-443.

36. Evans DG, Laloo F, Howell S, Verhoef S, Woodward ER, Howell A. Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens. Breast Cancer Res Treat. 2016;155:597-601.

37. Fountzilas E, Konstantopoulou I, Vagenas A, et al. Pathology of BRCA1- and BRCA2-associated breast cancers: known and less known connections. Clin Breast Cancer. 2020;20:152-159.

38. Grushko TA, Blackwood MA, Schumm PL, et al. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res. 2002;62:1481-1488.

39. Hagen AI, Bofin AM, Ytterhus B, et al. Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations. Acta Oncol. 2007;46:199-203.

40. He Y, Su Y, Zhou L. Expression of HER2 and BRCA1 correlates with prognosis in patients with breast cancer after radiotherapy: a case-control study [Epub ahead of print]. Cancer Biother Radiopharm. 2020. https://doi.org/10.1089/cbr.2020.3607.

41. Heeke AL, Xiu J, Elliott A, et al. Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. Breast Cancer Res Treat. 2020;184:265-275.

42. Holm K, Hegardt C, Staaf J, et al. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. 2010;12:R36.

43. Hsu NC, Huang YF, Yokoyama KK, Chu PY, Chen FM, Hou MF. Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer. PLoS One. 2013;8:e56256.

44. Hung FH, Wang YA, Jian JW, et al. Evaluating BRCA mutation risk predictive models in a Chinese cohort in Taiwan. Sci Rep. 2019;9:10229.

45. Hussein IA, Ahmed ST, Hameedi AD, et al. Immunohistochemical expression of BRCA1 protein, ER, PR and Her2/neu in breast cancer: a clinicopathological study. Asian Pac J Cancer Prev. 2020;21:1025-1029.

46. Huszno J, Koloza Z. Molecular characteristics of breast cancer according to clinicopathological factors. Mol Clin Oncol. 2019;11:192-200.

47. Jouhadi H, Tazitte A, Azedoug H, Naim A, Nadifi S, Benider A. Clinical and pathological features of BRCA1/2 tumors in a sample of high-risk Moroccan breast cancer patients. BMC Res Notes. 2016;9:248.

48. Gorodetska I, Kozeretska I, Dubrovskia A. BRCA genes: the role in genome stability, cancer stemness and therapy resistance. J Cancer. 2019;10:2109-2117.

49. Jung J, Kang E, Gwak JM, et al. Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients. Curr Oncol. 2016;23:298-303.

50. Kim D, Jung W, Koo JS. The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes. J Korean Med Sci. 2011;26:352-359.

51. Kim S, Rimm D, Carter D, et al. BRCA status, molecular markers, and clinical variables in early, conservatively managed breast cancer. Breast J. 2003;9:167-174.

52. Krammer J, Pinker-Domenig K, Robson ME, et al. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2017;163:505-517.

53. Kurian AW, Ward KC, Howlader N, et al. Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. J Clin Oncol. 2019;37:1305-1315.

54. Kwong A, Wong LP, Wong HN, et al. Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer. Hugo J. 2009;3:63-76.

55. Lang GT, Shi JX, Hu X, et al. The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: screening of 2,991 patients and 1,043 controls by next-generation sequencing. Int J Cancer. 2017;141:129-142.

56. Lin PH, Kuo WH, Huang AC, et al. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer. Oncotarget. 2016;7:8310-8320.

57. Lagos-Jaramillo VI, Press MF, Ricker CN, Dubeuau L, Mai PL, Weitzel JN. Pathological characteristics of BRCA-associated breast cancers in Hispanics. Breast Cancer Res Treat. 2011;130:281-289.

58. Litwiniuk MM, Roznowski K, Filas V, et al. Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers. BMC Cancer. 2008;8:100.

59. Madaras L, Balint N, Gyoryffy B, et al. BRCA mutation-related and claudin-low breast cancer: blood relatives or step-sisters. Pathobiology. 2016;83:1-12.

60. Manie E, Popova T, Battistella A, et al. Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas. Int J Cancer. 2016;138:891-900.

61. McCrorie AD, Ashfield S, Begley A, et al. Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers. J Pathol Clin Res. 2020;6:146-153.

62. Moorman PG, Iversen ES, Marcom PK, et al. Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multicenter case-only analysis. Breast Cancer Res Treat. 2010;124:441-151.

63. Musolino A, Bella MA, Bortesi B, et al. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study. Breast. 2007;16:280-292.

64. Nahlezh L, Otokushe S, Dwivedi AK, et al. Clinical and pathological characteristics of Hispanic BRCA-associated breast cancers in the American-Mexican border city of El Paso, TX. Am J Cancer Res. 2015;5:466-471.

65. Noh JM, Choi DH, Nam SJ, et al. Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients. Breast Cancer Res Treat. 2012;131:217-222.

66. Noori SF, Gangi A, Nelson ME, et al. Comparison of nodal metastasis between BRCA mutation carriers and non-BRCA mutation carriers with breast cancer. Ann Surg Oncol. 2014;21:3324-3329.

67. Ottini L, Silvestri V, Rizzolo P, Falchetti M, Zanna I, Saieva C, et al. Clinical and pathologic characteristics of BRCA1/2, positive male breast cancer patients: results from a collaborative multicenter study in Italy. Breast Cancer Res Treat. 2012;134:411-418.

68. Park B, Sohn JY, Yoon KA, et al. Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients. Breast Cancer Res Treat. 2017;163:139-150.

69. Parvin S, Islam MS, Al-Mamun MM, et al. Association of BRCA1, BRCA2, RAD51, and HER2 gene polymorphisms with the breast cancer risk in the Bangladeshi population. Breast Cancer. 2017;24:229-237.

70. Plevova P, Cerna D, Balcar A, et al. CCND1 and ZNF217 gene amplification and tumor characteristics in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019;2481-2501.
72. Quenneville LA, Phillips KA, Ozcelik H, et al. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. *Cancer*. 2002;95:2068-2075.
73. Querzoli P, Albonico G, di Iasio MG, et al. Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women. *Breast Cancer Res Treat*. 2001;66:135-142.
74. Rana HQ, Sacca R, Drogan C, et al. Prevalence of germline variants in inflammatory breast cancer. *Cancer*. 2019;125:2194-2202.
75. Robson M, Rajan P, Rosen PP, et al. BRCA-associated breast cancer: absence of a characteristic immunophenotype. *Cancer Res*. 1998;58:1839-1842.
76. Soenderstrup IMH, Laenkholm AV, Jensen MB, et al. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG. *Acta Oncol*. 2018;57:95-101.
77. Tung N, Wang Y, Collins LC, et al. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. *Breast Cancer Res*. 2010;12:R12.
78. Vos S, Elias SG, van der Groep P, Smolders YH, van Gils CH, van Diest PJ. Comprehensive proteomic profiling-derived immunohistochemistry-based prediction models for BRCA1 and BRCA2 germline mutation-related breast carcinomas. *Am J Surg Pathol*. 2018;42:1262-1272.
79. Wei JT, Huang WH, Du CW, et al. Clinicopathological features and prognostic factors of young breast cancers in Eastern Guangdong of China. *Sci Rep*. 2014;4:5360.
80. Xu J, Wang B, Zhang Y, Li R, Wang Y, Zhang S. Clinical implications for BRCA gene mutation in breast cancer. *Mol Biol Rep*. 2012;39:3097-3102.
81. Yip CH, Taib NA, Choo WY, Rampal S, Thong MK, Teo SH. Clinical and pathologic differences between BRCA1-, BRCA2-, and non-BRCA-associated breast cancers in a multiracial developing country. *World J Surg*. 2009;33:2077-2081.
82. You C, Xiao Q, Zhu X, et al. The clinicopathological and MRI features of patients with BRCA1/2 mutations in familial breast cancer. *Gland Surg*. 2021;10:262-272.
83. Yu JH, Lee JW, Son BH, et al. Characteristics of BRCA1/2 mutation-positive breast cancers in Korea: a comparison study based on multi-center data and the Korean breast cancer registry. *J Breast Cancer*. 2014;17:129-135.
84. Zavitsanos PJ, Wazer DE, Hepel JT, Wang Y, Singh K, Leonard KL. BRCA1 mutations associated with increased risk of brain metastases in breast cancer: a 1: 2 matched-pair analysis. *Am J Clin Oncol*. 2018;41:1252-1256.
85. Zhang J, Pei R, Pang Z, et al. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer. *Breast Cancer Res Treat*. 2012;132:421-428.
86. Lambertini M, Ameye L, Hamey A, et al. Pregnancy after breast cancer in patients With germline BRCA mutations. *J Clin Oncol*. 2020;38:3012-3023.
87. Klapper LN, Glathe S, Vaisman N, et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. *Proc Natl Acad Sci U S A*. 1999;96:4995-5000.
88. Rippinger N, Fischer C, Sinn HP, et al. Breast cancer characteristics and surgery among women with Li-Fraumeni syndrome in Germany-A retrospective cohort study. *Cancer Med*. 2021;10:7747-7758.